By Editorial TeamIn digital health, patient engagement drives clinical outcomes, period. For investors scouting the next pre-IPO AI health companies, the real question is which platforms can actually keep patients locked in, especially in the high-stakes world of heart health. This is a breakdown of the strategies top private companies are using to see if they can use AI and mobile apps to pull apart traditional chronic disease management.
The Unbundling of Chronic Care: Mobile-First Engagement
The old clinic-first model for managing chronic disease is being picked apart, and mobile apps are taking over, piece by piece. This is happening across healthcare, but it’s especially true for cardiovascular health, where sticking to a plan for lifestyle and meds is everything. An app that keeps a user’s attention can make a real difference in their health. So we’re looking for the “next big thing” by finding companies that can show people stick around for the long haul, not just companies with a big spike in sign-ups that fade away.
Benchmarking Engagement: Hello Heart’s Blueprint
Hello Heart is a big name in digital heart health, and they’ve set the standard for making an app that people actually use and that gets results. Their formula works because the app is dead simple to use and it gives people personalized feedback and advice on their phone that they can actually do something with. For any company trying to be a leader here, you have to meet or beat Hello Heart’s distribution, their penetration with health plans, and their published outcomes, that’s a baseline signal for your valuation. This means proving you can get persistent daily active usage, which is a far better predictor of whether a digital tool is working than just counting how many people downloaded it.
Engagement Strategies: Omada Health vs. Hinge Health
To get a feel for how AI can drive engagement in heart health, it’s worth looking at two established digital health platforms: Omada Health and Hinge Health. Neither is a pure-play cardiac AI company, but their work in chronic care gives us a good look at what it takes to build scalable engagement models and use AI for personalization.
Omada Health: A Broad Chronic Care Platform
Omada Health, a very well-funded platform, is a good example of a company taking on digital health from all angles. Their platform isn’t just for one thing. It covers a range of chronic diseases like diabetes and hypertension, which are huge risk factors for heart disease. The fact that the company pulled in serious money, including a $150 million IPO in June 2025, shows that investors believe in what they’re doing. Omada Health is now a public company. Oak HC/FT Omada Health funding announcement June 2025 Omada’s whole engagement model is built on personalized coaching, digital education, and peer groups, all delivered through their app. Their AI personalizes the content and the interventions for each user to keep them on track with their health goals. Their list of enterprise contracts and deep health plan penetration shows they have a solid distribution model. But to compare them directly to a heart-health specialist, you’d have to look closely at their published outcomes just for cardiovascular metrics. The real question for Omada is whether a generalist platform can get the same deep engagement and clinical results for a specific condition that a focused solution can.
Hinge Health: The Musculoskeletal Engagement Benchmark
Hinge Health is the leader in digital musculoskeletal (MSK) care, and they’re a fantastic benchmark for what real engagement looks like in digital health. How they got people to consistently stick with their physical therapy programs at home has a lot to teach the heart health world. Hinge Health keeps users coming back with a mix of AI-powered exercise feedback, personal coaching, and a gamified app. Their clinical studies back this up, showing strong engagement numbers and real clinical improvements for MSK issues. Peer-reviewed engagement studies for Hinge Health The main lesson from Hinge is that AI personalization, when delivered through a slick mobile interface, creates a feedback loop that gets people to open the app every day. This means the app has to actively adapt to the user’s progress, their preferences, and whatever is getting in their way. While fixing a bad back isn’t the same as managing heart disease, the psychology of behavior change and digital interaction is totally transferable. Investors should be demanding this same level of personalization and adaptive feedback from any heart health company.
Specialized Cardiovascular AI Approaches
Omada and Hinge are useful comparisons, but the prompt was about startups using AI to get people more engaged in their heart health through mobile apps. That brings us to companies that are either 100% focused on cardiovascular disease or are using serious AI to solve specific heart-related problems.
Tempus AI: Precision Data and Broader Implications
To understand the potential of a true data-and-AI-driven company, look at Tempus AI. They’re mostly known for their work in oncology, but they show what’s possible. Now public, Tempus AI’s market cap of around $12.8 billion and its backing from GV shows that investors have a huge appetite for AI-native companies that build a business on top of massive datasets. Tempus’s real power is its machine for collecting, structuring, and analyzing huge amounts of clinical and molecular data to help doctors make better treatment decisions. They aren’t focused on a consumer-facing heart health app, but their work with AI and creating data moats shows how important a solid data infrastructure is. A “Tempus model” for heart health would be a platform that could ingest all kinds of cardiovascular data, ECGs, BP readings, lab results, imaging, lifestyle data from a wearable, process it all with smart AI, and then deliver incredibly personal and actionable advice straight to a patient’s phone. This requires more than just a slick app. It requires a deep knowledge of cardiac pathophysiology and the ability to plug into clinical workflows, maybe even as a SaMD solution.
Scoring Rubric for Investor Evaluation
Here’s a quick and dirty rubric for scoring potential winners in the AI-driven mobile heart health space, based on signals that set a floor for valuation: 1. User Retention Metrics: Forget download numbers. What are the 30-day, 90-day, and 1-year retention rates? What’s your daily active user (DAU) to monthly active user (MAU) ratio? People sticking around is what proves your solution is valuable.
- Clinical Trial Engagement Data: Has the company published peer-reviewed studies that show both the clinical outcomes and the engagement levels that produced them? You need to see adherence rates, completion rates, and how long people kept using the tool in a trial. Peer-reviewed engagement studies for Omada Health
- Funding Velocity and Quality: The speed of funding rounds and who is writing the checks are strong signals of market confidence and a company that knows how to operate. Getting big checks from top-tier VCs like Oak HC/FT (like Omada) or GV (like Tempus) means the smart money thinks you have a real business.
- Enterprise Contract Breadth and Health Plan Penetration: You can’t scale a digital health company without getting employers and health plans to buy in. A long list of contracts proves you’ve got a good go-to-market strategy and that payers agree your solution is worth paying for.
- Outcomes Publication History: At the end of the day, the app has to make people healthier. A strong history of publishing positive clinical outcomes in respected journals proves the platform works and is trustworthy, which is what you need to get reimbursement and expand your market.
- AI-Native Architecture and Data Moat: Was the company built around AI from day one, or is it a feature they bolted on later? A true AI-native company has a “data moat”, a proprietary dataset that makes its models better and is hard for anyone else to copy. This is your long-term defense.
Conclusion
For investors, it’s simple: back the platforms that can prove people use them for the long haul, not just for a few weeks. The next big thing in mobile heart health won’t be just a new algorithm. It’ll be a complete solution that masterfully combines AI with a user experience that people don’t want to put down. The companies that can show you the data, for engagement, for clinical outcomes, and for enterprise sales, are the ones that are set for major pre-IPO growth and a strong debut on the public markets. The old way of delivering care is coming apart fast, and the platforms that can rebundle care around a personal, effective, AI-driven mobile experience will win this market.
Frequently Asked Questions
What is the primary focus for investors in the pre-IPO AI health market, particularly in heart health?
For investors, the primary focus is on identifying platforms that can sustain long-term patient engagement, as engagement directly correlates with clinical outcomes. This is especially critical in heart health where adherence to lifestyle changes and medication significantly impacts outcomes. Investors seek companies demonstrating persistent daily active usage rather than short-term sign-up spikes.
What are key indicators of success for a digital heart health company, based on the article’s benchmarks?
Key indicators of success include matching or exceeding Hello Heart’s distribution breadth, health plan penetration, and published outcomes. This involves demonstrating not just initial adoption, but also persistent daily active usage, which is a more accurate predictor of clinical efficacy in digital interventions. Strong engagement metrics and positive clinical outcomes are crucial.
How do broader chronic care platforms like Omada Health demonstrate investor confidence, and what are their challenges in heart health?
Omada Health exemplifies investor confidence through its comprehensive approach to digital health, addressing a spectrum of chronic diseases including those that are risk factors for cardiovascular disease, and attracting substantial investment leading to its IPO. However, the challenge for Omada, as a broader platform, is to demonstrate the same depth of engagement and clinical impact in specific conditions like heart health as a specialized solution might.
What lessons can be learned from Hinge Health’s success in engagement that are transferable to heart health solutions?
Hinge Health’s success in driving sustained user participation in musculoskeletal care highlights that AI-driven personalization, delivered through an intuitive mobile interface, can create feedback loops that drive daily active usage. This involves actively adapting to user progress, preferences, and barriers to engagement. Investors should look for similar levels of personalization and adaptive feedback in heart health solutions.
